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Early Diagnosis in Pulmonary Arterial Hypertension: The Search for the
Holy Grail
Idiopathic or heritable pulmonary arterial hypertension (I/H-PAH)
in children is a progressive, incurable pulmonary vascular
disease (1). In the last two decades, speciﬁc PAH-targeted
therapies have emerged that were positively trialed for efﬁcacy
only in adults but are currently also used and recommended
in children (2). Despite these therapies, however, the prognosis
for a child who has received a diagnosis of PAH remains
unfavorable, with an estimated 5-year transplant-free survival
rate of around 60% (3). Early diagnosis and treatment of this
disease have been associated with improved long-term survival.
Therefore, screening patients at risk for developing PAH seems to
be a rational approach to detect the disease early and improve
outcomes (4, 5).
In this issue of the Journal, Sawada and colleagues (pp. 1397–
1406) investigate the impact of a school ECG-based cardiovascular
screening program on detecting I/H-PAH in a general population
of Japanese schoolchildren (6). The authors, as well as the Japanese
Pediatric Cardiac Society, have to be commended for this excellent
and unique effort, as no such large-scale ECG screening program
for pulmonary hypertension (PH) in children has ever been
reported.
This Japanese ECG-based screening program also includes a
questionnaire and physical examination, and the authors report
that this program detected a unique subpopulation of pediatric
patients with I/H-PAH who had only mild clinical symptoms
(lower World Health Organization functional classiﬁcation and
longer 6-min-walk distance) without obvious right ventricular
(RV) failure (lower plasma brain natriuretic peptide), but
nevertheless established PH (mean pulmonary arterial pressure
[mPAP] 616 17 mm Hg and pulmonary vascular resistance index
186 8 Wood units [WU] $m2).
Initially, PAH is a clinically silent disease. Then, relatively late
in its natural history, the PAP rises, at which point more than 60%
of the small, distal pulmonary arteries have been obliterated. So,
although the children identiﬁed by the screening program were
considered to have no or only mild symptoms, with an mPAP
of 61 mm Hg and a pulmonary vascular resistance index
of 18 WU $m2, their PAH may be detected earlier than without
screening, but this is far from a true early diagnosis of PAH. One
may speculate that the identiﬁed children, who had a more
preserved RV function, were able to adapt well to the disease. Initial
symptoms in pediatric I/H-PAH occur only after the RV fails to
adapt to the increased afterload; furthermore, they are nonspeciﬁc
and include symptoms such as fatigue and exertional dyspnea.
Consequently, the delay between the onset of symptoms and a
diagnosis of pediatric PAH is reported to be around 1.5 years (1).
So, does this early detection of a subset of children with I/H-PAH
mean that the Japanese nationwide ECG-based screening of healthy
children is a successful screening strategy for PH? This program was
originally not designed for this speciﬁc purpose. Given the availability
of PAH-targeted therapies and the concept that outcomes can be
improved by earlier initiation of treatment, the identiﬁed children
may have improved outcomes compared with those who presented
with symptoms, which should be regarded a positive result of
the program. In this respect, however, the results of the current
study temper initial enthusiasm, as better outcomes could not
be demonstrated (yet). This may be related to either the retrospective
design of the study or the pulmonary hemodynamic proﬁles of the
children, which indicated that they had advanced vascular disease similar
to that observed in children not identiﬁed by the screening program (6).
In a screening program, the accuracy of the screening tool
or strategy used is important. In PAH, once changes in the
ECG are present, the RV has already adapted to the increased
afterload—in particular, hypertrophy and dilatation, which are
signs of relatively advanced disease. In other words, as discussed
appropriately by the authors, an ECG alone will detect patients
with signiﬁcantly increased PAP and is unlikely to detect really
early disease.
Moreover, the sensitivity of ECG for detecting RV
hypertrophy is reported to be 40–60% depending on the criteria
used, which increases the rate of false-negative results (7, 8).
More importantly, although the speciﬁcity of ECG for detecting
RV hypertrophy has been reported to be more than 90%, with
an estimated incidence of pediatric I/H-PAH of 0.5–0.7
cases/million children/yr and a low prevalence, the posttest positive
predictive value of the ECG for PAH will necessarily be low,
as a simple function of Bayesian analysis (9, 10). This will result
in a high number of false-positive results that will necessitate
subsequent diagnostic workups (invasive or noninvasive).
Unfortunately, the current study does not allow conclusions about
the accuracy of screening in terms of the number of missed
children with PAH (false negatives) or the number of patients with
ECG abnormalities who turned out not to have PAH (false
positives). These numbers are important to determine the cost
effectiveness of the screening program and relate directly to the
prevalence of the disease in the population. Therefore, most PAH
screening programs that are currently being evaluated focus
primarily on high-risk groups with an increased pretest probability
for PH. These include individuals with the BMPRII mutation,
systemic sclerosis, portal hypertension, or sickle cell disease, as well
as preterm-born infants with bronchopulmonary dysplasia (5).
Once the PAH screening outcome is conﬁrmed, several
scenarios may be faced: 1) PAH is deﬁnitely present and the patient
is treated (a follow-up study should then prove that the diagnosis in
an asymptomatic patient would lead to a better outcome); 2) no
signs of PAH are present, which raises the question of whether the
patient should be rescreened, particularly in high-risk populations;
and 3) mPAP is abnormal but does not reach 25 mm Hg, which is
currently required for a deﬁnite diagnosis and treatment. Because
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normal PAP is considered to be 14.06 3.3 mm Hg, at the 6th
World Symposium on Pulmonary Hypertension held in Nice in
2018, a change in the deﬁnition of PAH was proposed that would
decrease the lower limit of mPAP to 20 mm Hg and a pulmonary
vascular resistance. 3 WU; however, no conclusion was made
regarding whether patients with an mPAP between 20 and 25 mm
Hg should be treated (11).
The ability to obtain an early diagnosis in PAH remains
an important goal to be pursued. Sawada and colleagues have
contributed to this quest by evaluating the performance of a
large ECG-based screening program in healthy schoolchildren.
Unfortunately, the studied screening program did not resolve this
problem, and thus early diagnosis remains an important goal to
pursue in children with PAH. n
Author disclosures are available with the text of this article at
www.atsjournals.org.
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Smooth Muscle Cells: A Novel Site of P-Selectin Expression
with Pathophysiological and Therapeutic Relevance in
Pulmonary Hypertension
Pulmonary arterial hypertension (PAH) is a debilitating disease
associated with increased pulmonary artery pressures, reduced lung
function and exercise ability, and progressive right heart failure (1).
Endothelial dysfunction, vasoconstriction, pulmonary vascular
remodeling secondary to smooth muscle cell proliferation and
hypertrophy, muscularization of precapillary arterioles, and distal
vessel loss are among the key pathophysiological processes in
PAH (2). Present pharmacologic interventions target primarily
vasoconstriction and are, as such, able to slow down, but not
reverse, disease progression. Hence, therapies that could reverse the
proliferative phenotype of pulmonary vascular cells and, thus,
improve RV function without causing adverse effects are highly
desirable (3).
P-selectin expressed on activated endothelium and platelets
promotes inﬂammation by serving as a ligand for PSGL-1
(P-selectin glycoprotein ligand-1) on leukocytes to mediate
leukocyte rolling and leukocyte–platelet aggregation, respectively
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